Global Oral Vaccines Market by Vaccine Type (Live Attenuated Oral Vaccines, Inactivated Oral Vaccines), by Therapeutic Area (Infectious Diseases, Cancer, Allergies), by End-Use Industry (Government Health Programs, Hospitals & Clinics, Pharmacies & Retail Healthcare, Biotechnology); Insights & Forecast (2024 – 2030)

As per Intent Market Research, the Oral Vaccines Market was valued at USD 5.2 Billion in 2024-e and will surpass USD 19.9 Billion by 2030; growing at a CAGR of 25.1% during 2025 - 2030.

The Oral Vaccines Market is expanding as an alternative to injectable vaccines, offering enhanced convenience and ease of administration. Oral vaccines, which are delivered via the digestive system, provide a more patient-friendly option compared to traditional injectable vaccines. This delivery method not only eliminates the need for syringes but also helps ensure that vaccines reach target populations in regions with limited healthcare infrastructure. The market's growth is largely driven by increased vaccination awareness, technological advancements, and the rising prevalence of infectious diseases. The potential to deliver vaccines for various therapeutic areas, including infectious diseases, cancer, and allergies, is further fueling the market's expansion.

Live Attenuated Oral Vaccines Segment Is Largest Owing to Efficacy and Strong Immunization Coverage

The live attenuated oral vaccines segment is the largest in the oral vaccines market, primarily due to their proven efficacy and ability to generate strong immune responses. Live attenuated vaccines contain weakened forms of pathogens, which stimulate the body’s immune system without causing the disease. This type of vaccine has been widely used for diseases like polio, rotavirus, and typhoid, providing long-lasting immunity and facilitating broad vaccination coverage.

The oral form of live attenuated vaccines enhances their appeal, especially in developing regions where injectable vaccines may be harder to administer and store. Their ease of administration, along with the high demand for vaccination in both developed and emerging markets, positions live attenuated oral vaccines as a dominant segment in the market.

Inactivated Oral Vaccines Segment Is Fastest Growing Owing to Safety Profile and Growing Applications

The inactivated oral vaccines segment is the fastest growing in the oral vaccines market, driven by their enhanced safety profile and stability. Unlike live attenuated vaccines, inactivated vaccines contain killed pathogens, which cannot cause disease, making them a safer option, particularly for individuals with compromised immune systems. These vaccines are also more stable under varying environmental conditions, which is advantageous in regions with limited cold chain infrastructure.

The expanding application of inactivated oral vaccines in diverse therapeutic areas, including infectious diseases, allergies, and cancer, is fueling the segment's rapid growth. The development of new inactivated vaccines targeting emerging health threats further contributes to the demand for this vaccine type, driving market expansion.

Infectious Diseases Segment Is Largest Therapeutic Area Owing to High Vaccination Demand

The infectious diseases therapeutic area is the largest segment in the oral vaccines market, driven by the high demand for vaccines to prevent diseases such as polio, rotavirus, cholera, and typhoid. Infectious diseases continue to pose a significant global health threat, particularly in developing countries where sanitation and healthcare access are limited. Oral vaccines are a key tool in controlling and preventing the spread of these diseases, as they are easier to administer and more cost-effective compared to injectable vaccines.

With the rise of vaccine-preventable diseases and the ongoing efforts of global health organizations to increase vaccination coverage, the infectious diseases segment holds a dominant share of the oral vaccines market. Mass immunization campaigns and the development of new oral vaccines for infectious diseases are expected to further boost market growth in this segment.

Government Health Programs Segment Is Largest End-Use Industry Owing to Mass Vaccination Efforts

The government health programs segment is the largest end-use industry in the oral vaccines market, owing to its pivotal role in implementing mass vaccination campaigns. Governments across the world, particularly in low- and middle-income countries, are increasingly using oral vaccines as part of their public health initiatives to control infectious diseases. These programs aim to increase vaccination rates and reduce the burden of diseases like polio, rotavirus, and cholera, which disproportionately affect underserved populations.

The ease of administering oral vaccines makes them an ideal choice for large-scale immunization efforts, helping governments reach rural and remote populations with minimal infrastructure. The significant involvement of government health programs in vaccine distribution is a major driver of the oral vaccines market's growth.

Asia Pacific Is Largest Region Owing to High Prevalence of Infectious Diseases and Vaccination Initiatives

Asia Pacific is the largest region in the oral vaccines market, primarily due to the high prevalence of infectious diseases and the increasing efforts to vaccinate large populations. Countries such as India, China, and Indonesia face significant challenges in controlling infectious diseases, making vaccination a crucial public health strategy. The adoption of oral vaccines in these regions is accelerating, as they provide a more feasible and efficient solution to widespread immunization efforts.

Additionally, global organizations such as the World Health Organization (WHO) and UNICEF are actively involved in promoting oral vaccination programs in Asia Pacific, further driving the market's growth in the region. The combination of public health initiatives, a large population base, and the high incidence of vaccine-preventable diseases positions Asia Pacific as the largest regional market for oral vaccines.

Competitive Landscape and Key Players

The Oral Vaccines Market is highly competitive, with major players such as GlaxoSmithKline, Merck & Co., and Sanofi Pasteur leading the development of oral vaccines. These companies have a strong presence in the vaccine market, leveraging their research and development capabilities to create innovative oral vaccine formulations for a range of therapeutic areas, including infectious diseases, cancer, and allergies.

The competitive landscape is characterized by ongoing research into new oral vaccine technologies, as well as collaborations between pharmaceutical companies, governments, and global health organizations to expand vaccine coverage. With an increasing emphasis on vaccination programs in emerging markets, these companies are focusing on improving vaccine accessibility and affordability. The market's future growth will be shaped by advancements in vaccine development and efforts to address global health challenges.

Recent Developments:

• GlaxoSmithKline launched an updated oral vaccine for rotavirus to provide broader protection and increase global accessibility.
• Serum Institute of India Pvt. Ltd. received regulatory approval for an oral cholera vaccine aimed at improving immunization efforts in endemic regions.
• Panacea Biotec introduced a new oral vaccine for typhoid fever, expanding its portfolio for infectious disease prevention in developing countries.
• Bharat Biotech announced the successful clinical trials of a new oral vaccine for dengue, aiming for future approval and market launch.
• Merck & Co., Inc. partnered with the WHO to distribute oral vaccines in underserved areas of Africa to combat polio outbreaks.

List of Leading Companies:

• GlaxoSmithKline
• Sanofi Pasteur
• Merck & Co., Inc.
• Serum Institute of India Pvt. Ltd.
• Indian Immunologicals Ltd.
• Panacea Biotec
• Bio-Med Pvt. Ltd.
• Bharat Biotech
• The Institute of Vaccines and Sera
• Beijing Tiantan Biological Products
• China National Biotec Group
• EuBiologics Co., Ltd.
• Novartis AG
• Crucell (Johnson & Johnson)
• Vaxine Pty Ltd.

Report Scope: